

RADEMATT

Jacobus M. LEMMENS et al.

Examiner: PULLIAM, Amy

Serial No. 10/024,520

In re Application of

Group Art Unit: 1615

Filed:

December 21, 2001

Docket No.:

SYN-0011

For:

AMLODIPINE FREE BASE

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents and Trademarks P.O. Box 1450 Alexandria, VA 22313-1450 April 5, 2004

Sir:

Applicants hereby submit a copy of each document listed on the attached PTO-1449

Form for entry into the above-identified application and consideration by the Examiner. The non-US patent documents, which are in the English language, were cited in the International Search Report for the corresponding PCT application (copy also enclosed).

Applicants wish to advise the Examiner that a German Utility Model, which is based on the same priority applications as the present application, has been opposed in a nullity proceeding. The art cited therein is already of record in the present application. If the Examiner would like any additional information regarding the nullity proceeding, she is encouraged to contact applicants' undersigned application.

This Information Disclosure Statement is being submitted before a first Office Action on the merits under 37 C.F.R. § 1.97(b), and thus no fee is due.

Serial No. 10/024,520

This Statement should not be construed as a representation that a search has been made,

that information cited in the statement is considered to be and/or is material to patentability, that

the listed documents are available as prior art, or that information more material to examination

of the present patent application does not exist. The Examiner is specifically requested not to

rely solely on the documents submitted herewith.

Having complied with rules 97 and 98, applicants request that the listed documents be

officially considered by the Examiner, that the Examiner initial and return a copy of the 1449

Form, and that the listed documents be printed among the "References Cited" on any patent to

issue from this application.

Should the Examiner have any questions regarding this application, the Examiner is

requested to contact applicants' representative, Mark R. Buscher (Reg. No. 35,006) at telephone

number 703 753 5256.

Respectfully submitted,

Mark R. Buscher

Registration No. 35,006

P.O. Box 161

Catharpin, VA 20143

703 753 5256

2

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Application Number	10/024,520	
Filing Date	12/21/2001	
First Named Inventor	LEMMENS, et al	
Art Unit	1615	
Examiner Name	Pulliam, Amy	
Attorney Docket Number	SYN-0011	

Complete if Known

			U. S. PATEN	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (If known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code			<u> </u>
		^{US-} 6680334	01-20-2004	Bentham et al.	
		US-			
-		US-			
		US-			· · · · · · · · · · · · · · · · · · ·
		US-			
		US-			
		US-			
		US-			
		US-			

	FOREI	IGN PATENT DOCU	IMENTS		
Cite No.1	Foreign Patent Document Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T⁵
	WO 95/05822	03-02-1995	Pfizer Limited		
	WO 01/74390	10-11-2001	Pfizer Limited		
	EP 1 181 932	02-27-2002	Pfizer Limited		
		Cite No.1 Foreign Patent Document	Cite No.1 Foreign Patent Document Publication Date MM-DD-YYYY	Date MM-DD-YYYY	Cite No.1 Foreign Patent Document Publication Date MM-DD-YYYY Name of Patentee or Applicant of Cited Document Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear WO 95/05822 03-02-1995 Pfizer Limited WO 01/74390 10-11-2001 Pfizer Limited

Examiner	Date	
Signature	Considered	
. •		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.